Claims for Patent: 8,614,235

Summary for Patent: 8,614,235

Title:	CAI-based systems and methods for the localized treatment of ocular and other diseases
Abstract:	The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies) that are effective and are associated with little or no adverse side effects.
Inventor(s):	Robinson; Gary (Framingham, MA), Shapiro; Gideon (Gainesville, FL), Franklin; Alan J. (Mobile, AL), Jurczyk; Simona (Gainesville, FL)
Assignee:	RFE Pharma LLC (Framingham, MA)
Application Number:	13/181,847
Patent Claims:	1. A method for treating a patient suffering from age-related macular degeneration or diabetic retinopathy comprising: (a) diagnosing age-related macular degeneration or diabetic retinopathy in a patient; and (b) ocularly administering to said patient a sterile, aqueous suspension formulation free of organic solvents comprising: about 0.1 to about 2% w/v of suspended solid microparticulates of CAT (5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carbox- amide) in free base form; 0.051% w/v of Monobasic Sodium Phosphate Dihydrate; 0.5% w/v of Dibasic Sodium Phosphate Dodecahydrate; 0.05 to 0.4% w/v of Tyloxapol; and 0.76% w/v of Sodium Chloride; wherein the aqueous suspension formulation is at a pH from about 5.0 to 8.4, and wherein the ocular administration is by intravitreal injection. 2. The method of claim 1, wherein the sterile, aqueous formulation is a time-release formulation. 3. The method of claim 1, wherein the aqueous suspension formulation further comprises any one or combination of substances selected from the group consisting of pharmaceutically acceptable carriers, auxiliary substances, diluents, surfactants, detergents, stabilizers, excipients, and delivery-enhancing agents. 4. The method of claim 1, wherein the microparticulates of CAI are surface stabilized particles. 5. The method of claim 4, wherein the surface stabilization of the surface stabilized particles of CAI is provided by a pharmaceutically acceptable surface active agent selected from the group consisting of lecithin, charged or uncharged phospholipids, polymeric surfactants, non-polymeric surfactants, charged surfactants, uncharged surfactants, and one or more of bile acids and their salts. 6. The method of claim 4, wherein the aqueous suspension formulation further comprises any one or combination of materials selected from the group consisting of pharmaceutically acceptable diluents, viscosity-modifiers, and stabilizers. 7. The method of claim 1, wherein the aqueous suspension formulation further comprises beta-cyclodextrin. 8. The method of claim 1, wherein the aqueous suspension formulation further comprises hydroxypropyl .beta.-cyclodextrin. 9. The method of claim 1, wherein the size of the solid microparticulates of CAI is 10 micrometers or less. 10. The method of claim 1, wherein the aqueous suspension formulation further comprises ranibizumab (Lucentis.RTM.) or pegatanib (Macugen.RTM.).

Details for Patent 8,614,235

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2024-09-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2024-09-24
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2024-09-24